Patents Assigned to Astellas Pharma Inc.
  • Publication number: 20220275359
    Abstract: [Problem to be Solved] To provide a guide RNA. [Solution] A guide RNA for editing a target RNA sequence, comprising an antisense nucleotide sequence complementary to a portion of the target RNA sequence, a short-chain ADAR-recruiting nucleotide sequence, and at least one functional nucleotide sequence.
    Type: Application
    Filed: July 31, 2020
    Publication date: September 1, 2022
    Applicants: Astellas Pharma Inc., Fukuoka University
    Inventors: Eiji YOSHIMI, Yukari MORIYA, Mariko MANDA, Masatora FUKUDA
  • Patent number: 11414456
    Abstract: The present application provides a cell penetrating peptide consisting of the amino acid sequence of SEQ ID NO: 1, a cell penetrating peptide consisting of the amino acid sequence of SEQ ID NO: 2 and a cell penetrating peptide consisting of the amino acid sequence of SEQ ID NO: 3; and a complex comprising any one of the cell penetrating peptide and a functional molecule.
    Type: Grant
    Filed: December 10, 2018
    Date of Patent: August 16, 2022
    Assignees: Astellas Pharma Inc., National Center for Global Health and Medicine, Hiroshima University
    Inventors: Hideki Endo, Yukihito Ishizaka, Akira Ishiguro, Tomoki Takashina, Takashi Yamamoto, Tetsushi Sakuma
  • Publication number: 20220233721
    Abstract: Polynucleotides comprising the following base sequences: (a) a base sequence encoding a fusion protein of a nuclease-deficient CRISPR effector protein and a transcriptional repressor, and (b) a base sequence encoding a guide RNA targeting a continuous region of 18 to 24 nucleotides in length in a region set forth in SEQ ID NO: 127, SEQ ID NO: 46, SEQ ID NO: 128, SEQ ID NO: 129, SEQ ID NO: 130, SEQ ID NO: 131, SEQ ID NO: 132, SEQ ID NO: 88, SEQ ID NO: 91, SEQ ID NO: 133, SEQ ID NO: 137, SEQ ID NO: 117, or SEQ ID NO: 119 in an expression regulatory region of a human DMPK gene, are expected to be useful for treating muscular dystrophy.
    Type: Application
    Filed: May 27, 2020
    Publication date: July 28, 2022
    Applicants: Astellas Pharma Inc., Modalis Therapeutics Corporation
    Inventors: Eiji YOSHIMI, Tomoya OE, Tetsuya YAMAGATA, Keith M. CONNOLLY
  • Patent number: 11395852
    Abstract: The present invention generally provides a therapy for effectively treating and/or preventing diseases associated with cells expressing CLDN18.2, in particular cancer diseases such as gastroesophageal cancer. Data are presented demonstrating that administration of an anti-CLDN18.2 antibody to human patients with gastroesophageal cancer is safe and well-tolerated up to a dose of at least 1000 mg/m2. Furthermore, data are presented demonstrating that the antibody is fully functional in these patients to execute anti-tumor cell effects and evidence for antitumoral activity was obtained.
    Type: Grant
    Filed: October 11, 2018
    Date of Patent: July 26, 2022
    Assignees: Astellas Pharma Inc., TRON—Translationale Onkologie an der Universitätmedizin der Johannes Gutenberg-Universität Mainz Gemeinnützige GmbH
    Inventors: Ugur Sahin, Özlem Türeci
  • Patent number: 11390652
    Abstract: It is intended to provide a fusion polypeptide that regulates the transcription of a target gene. The present inventors have provided a fusion polypeptide comprising: a cell-penetrating peptide; a DNA-binding polypeptide; and a transcriptional regulator.
    Type: Grant
    Filed: December 11, 2017
    Date of Patent: July 19, 2022
    Assignees: Astellas Pharma Inc., National Center for Global Health and Medicine, Hiroshima University
    Inventors: Hideki Endo, Yukihito Ishizaka, Takashi Yamamoto, Tetsushi Sakuma
  • Patent number: 11376328
    Abstract: Provided is a pharmaceutical composition in which the solubility and/or dissolution properties of a poorly-soluble drug can be improved. The pharmaceutical composition comprises a poorly-soluble drug, and polyvinyl alcohol having a saponification degree of 63 mol % or more and 67 mol % or less.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: July 5, 2022
    Assignee: Astellas Pharma Inc.
    Inventors: Takatsune Yoshida, Hiroyuki Kojima, Yoshiaki Umemoto, Sachie Namiki, Akira Takagi, Ken Shimada
  • Patent number: 11344589
    Abstract: The present invention provides a genetically recombinant vaccinia virus effective in preventing or treating cancer. Specifically, the present invention provides a recombinant vaccinia virus lacking functions of VGF and O1L and having a gene encoding B5R in which an SCR domain has been deleted. Specifically, the present invention provides a vaccinia virus comprising two polynucleotides, a polynucleotide encoding IL-7 and a polynucleotide encoding IL-12; a combination kit of two vaccinia viruses, a vaccinia virus comprising a polynucleotide encoding IL-7 and a vaccinia virus comprising a polynucleotide encoding IL-12; and use of the two vaccinia viruses in combination.
    Type: Grant
    Filed: April 30, 2020
    Date of Patent: May 31, 2022
    Assignees: National University Corporation Tottori University, Astellas Pharma Inc.
    Inventors: Takafumi Nakamura, Hajime Kurosaki, Motomu Nakatake
  • Publication number: 20220143263
    Abstract: Provided is a thrombin-carrying hemostatic sheet that is suitable for hemostasis during surgery, in particular, for hemostasis during spine surgery, that is convenient without preparation before use, and that is bioabsorbable and can be embedded in the body as it is. The hemostatic sheet is composed of a gelatin sponge carrying an effective amount of thrombin, wherein (A) the density is 30 to 55 mg/cm3, and (B) the shape maintaining angle in wet conditions is 55 to 120°.
    Type: Application
    Filed: March 19, 2020
    Publication date: May 12, 2022
    Applicants: Astellas Pharma Inc., National University Corporation Tokyo Medical and Dental University
    Inventors: Makoto OGINO, Keiichi YOSHIHARA, Yasuharu KIMURA, Megumi AOKI, Toshitaka YOSHII, Satoru EGAWA
  • Patent number: 11312966
    Abstract: [Problem] To provide a nucleic acid expected to be useful for treating mite allergy. [Means to be solved] Provided is a nucleic acid comprising a nucleotide sequence encoding a chimeric protein, wherein the nucleic acid comprises a nucleotide sequence encoding a signal peptide, a nucleotide sequence encoding an intra-organelle stabilizing domain of LAMP, a nucleotide sequence encoding an allergen domain comprising Der p 1, Der p 2, Der p 23, and Der p 7, a nucleotide sequence encoding a transmembrane domain and a nucleotide sequence encoding an endosomal/lysosomal targeting domain of LAMP in this order.
    Type: Grant
    Filed: July 15, 2021
    Date of Patent: April 26, 2022
    Assignee: Astellas Pharma Inc.
    Inventors: Takanori Marui, Masao Uchida
  • Patent number: 11286459
    Abstract: An object of the present invention is to provide an animal cell culture method which is high in protein productivity. Provided is a method for culturing animal cells in a culture medium, wherein the culture medium comprises a nucleic acid component(s) (deoxyuridine, thymidine, and/or deoxycytidine, or a salt(s) thereof). Also provided is a method for producing a protein, the method comprising the step of culturing animal cells expressing the protein in a culture medium, wherein the culture medium comprises a nucleic acid component(s).
    Type: Grant
    Filed: May 26, 2016
    Date of Patent: March 29, 2022
    Assignee: Astellas Pharma Inc.
    Inventors: Yasuhiro Takagi, Takuya Kikuchi
  • Publication number: 20220089455
    Abstract: [Problem] A novel method for producing a nanoparticle having a metal particle which contains iron oxide to which one or more hydrophilic ligands are coordination bonded is provided, where the nanoparticle is useful as a contrast agent for magnetic resonance imaging. [Means for Solution] As the novel method for producing a nanoparticle having a metal particle which contains iron oxide to which one or more hydrophilic ligands are coordination bonded, by performing ligand exchange to a hydrophilic ligand from an iron oxide nanoparticle having a surface to which a hydrophobic ligand is coordination bonded in one step using a phase transfer catalyst, it is possible to expect shortening of production processes and reduction of hydrophilic ligands used. Furthermore, by producing an iron oxide nanoparticle having a surface to which a hydrophobic ligand is coordination bonded using a dropwise addition method, it is possible to avoid a rapid temperature rise and a reaction at a high temperature of 200° C.
    Type: Application
    Filed: December 27, 2019
    Publication date: March 24, 2022
    Applicant: ASTELLAS PHARMA INC.
    Inventors: Takashi KIKUCHI, Tsuyoshi MIZUTANI, Hiroki TOYA, Akio KURODA, Yota GOTO, Shun HIRASAWA, Toshiyuki SUGIMORI
  • Patent number: 11279757
    Abstract: The invention relates to antibodies directed against an epitope located within the C-terminal portion of CLDN6 which are useful, for example, in diagnosing cancer and/or in determining whether cancer cells express CLDN6.
    Type: Grant
    Filed: September 5, 2018
    Date of Patent: March 22, 2022
    Assignees: Astellas Pharma Inc., TRON—Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz Gemeinnützige Gmbh
    Inventors: Rita Mitnacht-Kraus, Stefan Wöll, Korden Walter, Özlem Türeci, Ugur Sahin
  • Patent number: 11260124
    Abstract: To provide a superior anti-human NGF antibody Fab fragment that maintains a high neutralizing activity, and that reduces systemic side-effects arising from systemic exposure while expressing a local drug effect, and means for treating postoperative pain by using such antibody fragment. An anti-human NGF antibody Fab fragment comprising a heavy-chain fragment consisting of the amino acid sequence shown by SEQ ID NO:5 and a light-chain consisting of the amino acid sequence shown by SEQ ID NO: 8.
    Type: Grant
    Filed: May 20, 2016
    Date of Patent: March 1, 2022
    Assignee: Astellas Pharma Inc.
    Inventors: Hirotsugu Tanaka, Hirotada Fujita, Toshiaki Aoki
  • Publication number: 20220023422
    Abstract: Provided is a stable pharmaceutical composition, comprising an anti-human TSLP receptor antibody, capable of inhibiting the generation of chemically modified substances, such as deamidated forms and oxidized forms, or degradants or multimers. The pharmaceutical composition comprises an anti-human TSLP receptor antibody, a pharmaceutically acceptable buffer, arginine or a pharmaceutically acceptable salt thereof, and a surfactant.
    Type: Application
    Filed: February 10, 2021
    Publication date: January 27, 2022
    Applicant: ASTELLAS PHARMA INC.
    Inventors: Megumi IKEDA, Akinori CHIKUSHI
  • Publication number: 20220016239
    Abstract: [Problem to be Solved] Provided is an effective and safe method for treating or preventing a cancer using aAVC. [Solution] The present invention finds suitable ranges of the dose of ?-GalCer loaded on aAVC cell surface, and the amount of ?-GalCer loaded on aAVC cell surface in a pharmaceutical composition comprising aAVC, which are preferred in terms of securing effectiveness and safety in the treatment and prevention of a cancer using aAVC, and provides an effective and safe method for treating or preventing a cancer using aAVC, aAVC for effective and safe treatment or prevention of a cancer, and a pharmaceutical composition comprising the same, etc.
    Type: Application
    Filed: December 1, 2020
    Publication date: January 20, 2022
    Applicants: ASTELLAS PHARMA INC., RIKEN
    Inventors: Keisuke OHSUMI, Taku YOSHIDA, Masayuki KANKI, Shinichiro FUJII, Kanako SHIMIZU
  • Patent number: 11225642
    Abstract: The present invention provides: a method for producing renal progenitor cells from intermediate mesoderm cells, which comprises a step of culturing intermediate mesoderm cells in a medium containing a TGF? signaling activator(s) and a BMP inhibitor(s); the renal progenitor cells produced by the method; a pharmaceutical composition comprising the renal progenitor cells; and a therapeutic drug for kidney diseases comprising the renal progenitor cells.
    Type: Grant
    Filed: June 11, 2014
    Date of Patent: January 18, 2022
    Assignees: Kyoto University, Astellas Pharma Inc.
    Inventors: Kenji Osafune, Takafumi Toyohara, Yukiko Yamagishi
  • Publication number: 20210386826
    Abstract: Provided herein are methods and combinations for treating a subject having cancer by administering to the subject a PD-1/PD-L1 axis inhibitor, a CD-122-biased cytokine agonist, and an anti-androgen or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: November 4, 2019
    Publication date: December 16, 2021
    Applicants: Pfizer Inc., MERCK PATENT GMBH, NEKTAR THERAPEUTICS, Astellas Pharma Inc.
    Inventors: Christoffel Hendrik Boshoff, Rossano Cesari, Cristian Massacesi, Deborah Charych
  • Publication number: 20210388096
    Abstract: [Problem] Provided is an anti-human Fn14 antibody which binds to human Fn14 to inhibit an action via the human Fn14, thereby preventing or treating cancer cachexia. [Means for Solution] The inventors have conducted studies on an anti-human Fn14 antibody, and provided an anti-human Fn14 antibody comprising a heavy chain consisting of the amino acid sequence of SEQ ID NO: 2 and a light chain consisting of the amino acid sequence of SEQ ID NO: 4.
    Type: Application
    Filed: October 30, 2019
    Publication date: December 16, 2021
    Applicant: Astellas Pharma Inc.
    Inventors: Misato ITO, Risa KASHIWAGI, Masakatsu KAWAKAMI
  • Patent number: 11180554
    Abstract: [Problem] Provided is an anti-human CD73 antibody which is enhanced as compared to the antibody in the prior art and has an ability of recovering AMP-dependently suppressed T cell functions. [Means for Solution] Provided is an anti-human CD73 antibody comprising a heavy chain variable region comprising CDR1 consisting of the amino acid sequence of amino acid numbers 31 to 35 of SEQ ID NO: 2, CDR2 consisting of the amino acid sequence of amino acid numbers 50 to 66 of SEQ ID NO: 2, and CDR3 consisting of the amino acid sequence of amino acid numbers 99 to 112 of SEQ ID NO: 2, and a light chain variable region comprising CDR1 consisting of the amino acid sequence of amino acid numbers 24 to 34 of SEQ ID NO: 4, CDR2 consisting of the amino acid sequence of amino acid numbers 50 to 56 of SEQ ID NO: 4, and CDR3 consisting of the amino acid sequence of amino acid numbers 89 to 98 of SEQ ID NO: 4.
    Type: Grant
    Filed: December 12, 2017
    Date of Patent: November 23, 2021
    Assignee: Astellas Pharma Inc.
    Inventors: Masahito Sato, Hanae Toyonaga, Fumio Osaki, Tomohiro Eguchi
  • Patent number: RE49111
    Abstract: [Problem] To provide a compound which is useful as an active ingredient for a pharmaceutical composition for preventing or treating urine storage dysfunction, voiding dysfunction, lower urinary tract dysfunction, and the like. [Means for Solution] The present inventors have found that a thiazole derivative substituted with pyrazinylcarbonylamino at the 2-position is an excellent muscarinic M3 receptor-positive allosteric modulator and is expected as an agent for preventing or treating bladder/urinary tract diseases associated with bladder contractions via a muscarinic M3 receptor, thereby completing the present invention. 2-Acylaminothiazole derivative or a salt thereof of the present invention is expected as an agent for preventing or treating bladder/urinary tract diseases associated with bladder contractions via a muscarinic M3 receptor, for example voiding dysfunction such as underactive bladder.
    Type: Grant
    Filed: April 23, 2020
    Date of Patent: June 21, 2022
    Assignee: ASTELLAS PHARMA INC.
    Inventors: Taisuke Takahashi, Takanori Koike, Kenji Negoro, Hiroaki Tanaka, Jun Maeda, Kazuhiro Yokoyama, Hajime Takamatsu